CBIO - Catalyst Biosciences, Inc. Stock Price and Quote

CBIO [NASD]

Index	-	P/E	0.51	EPS (ttm)	0.38	Insider Own	0.10%	Shs Outstand	31.48M	Perf Week	-3.87%
Market Cap	6.94M	Forward P/E	-	EPS next Y	-0.21	Insider Trans	0.00%	Shs Float	27.91M	Perf Month	-34.01%
Income	11.90M	PEG	-	EPS next Q	-0.10	Inst Own	25.00%	Short Float / Ratio	2.66% / 0.44	Perf Quarter	-38.20%
Sales	3.20M	P/S	2.17	EPS this Y	2.10%	Inst Trans	-3.18%	Short Interest	0.74M	Perf Half Y	-34.52%
Book/sh	0.93	P/B	0.20	EPS next Y	-122.80%	ROA	22.60%	Target Price	-	Perf Year	75.59%
Cash/sh	0.63	P/C	0.30	EPS next 5Y	-	ROE	26.90%	52W Range	0.06 - 0.40	Perf YTD	-39.98%
Dividend	-	P/FCF	-	EPS past 5Y	33.30%	ROI	-213.90%	52W High	-51.29%	Beta	0.93
Dividend %	-	Quick Ratio	18.40	Sales past 5Y	79.00%	Gross Margin	-0.60%	52W Low	244.01%	ATR	0.02
Employees	45	Current Ratio	18.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	39.76	Volatility	7.14% 10.47%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	80.70%	Profit Margin	-	Rel Volume	0.07	Prev Close	0.19
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	0.00%	Avg Volume	1.69M	Price	0.20
Recom	2.70	SMA20	-8.33%	SMA50	-20.81%	SMA200	-34.37%	Volume	35,545	Change	3.16%

Apr-29-21

Resumed

Stephens

Overweight

$18 → $19

Feb-10-21

Initiated

Piper Sandler

Overweight

$15

May-21-20

Initiated

Raymond James

Outperform

$20

Jan-04-19

Initiated

Oppenheimer

Outperform

$24

Feb-12-18

Reiterated

B. Riley FBR, Inc.

Buy

$19 → $49

Feb-09-18

Reiterated

Chardan Capital Markets

Buy

$37.50 → $75

Feb-09-18

Reiterated

Chardan Capital Markets

Buy

$10 → $75

Dec-08-17

Initiated

B. Riley FBR, Inc.

Buy

$19

Jun-12-17

Initiated

Chardan Capital Markets

Buy

$10

Jun-06-17

Initiated

Ladenburg Thalmann

Buy

$11

Show Previous Ratings

Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 Insider Monkey
Feb-28-23 08:00AM	Catalyst Biosciences Provides Corporate Update GlobeNewswire +23.75%
Dec-27-22 07:00AM	Catalyst Biosciences Completes First Steps in Reverse Merger Plan GlobeNewswire
Nov-16-22 05:05AM	Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021) Simply Wall St.
Sep-19-22 09:43AM	Bullish insiders at Catalyst Biosciences, Inc. (NASDAQ:CBIO) loaded up on US$1.2m of stock earlier this year Simply Wall St.
04:05PM	Loading…
Sep-01-22 04:05PM	Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share GlobeNewswire
Aug-25-22 08:00AM	Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share GlobeNewswire
Aug-23-22 07:11AM	Catalyst Biosciences (NASDAQ:CBIO) investors are sitting on a loss of 71% if they invested three years ago Simply Wall St.
Aug-19-22 08:00AM	Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation GlobeNewswire
Aug-15-22 04:05PM	Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results GlobeNewswire
Aug-11-22 06:00AM	JDS1, LLC Terminates Proxy Contest at Catalysts 2022 Annual Meeting Business Wire
Aug-10-22 12:46PM	Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board GlobeNewswire
Aug-03-22 08:00AM	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote FOR All of the Companys Nominees on the WHITE Proxy Card GlobeNewswire
Aug-01-22 08:30AM	Catalyst Biosciences Publishes New Investor Presentation GlobeNewswire
07:30AM	Catalyst Biosciences Announces Support from Largest Single Stockholder GlobeNewswire
12:21PM	Loading…
Jul-22-22 12:21PM	JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders Business Wire
Jul-19-22 08:00AM	Catalyst Biosciences Sends Letter to Stockholders GlobeNewswire
Jul-14-22 09:40AM	Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? Zacks
Jul-06-22 08:00AM	Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling GlobeNewswire
Jun-29-22 08:00AM	Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders GlobeNewswire +13.25%
Jun-28-22 09:40AM	Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year? Zacks -5.03%
May-26-22 11:03AM	The Petri Dish: NIH gives $68M to Pfizer-partnered AI startup American City Business Journals -22.38%
May-23-22 09:57AM	Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex Benzinga +234.21%
08:30AM	Catalyst Biosciences Sells Complement Portfolio for $60 Million GlobeNewswire
May-09-22 08:30AM	Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results GlobeNewswire -11.42%
Apr-08-22 09:57AM	Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely Simply Wall St. -7.26%
Mar-31-22 08:00AM	Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Mar-15-22 05:00PM	Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIOs Complement Portfolio in Ophthalmology GlobeNewswire
Feb-17-22 08:00AM	Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives GlobeNewswire +6.40%
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... GuruFocus.com
08:00AM	Loading…
Jan-25-22 08:00AM	Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency GlobeNewswire -7.05%
Jan-12-22 12:00PM	Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know Zacks
Dec-20-21 07:51PM	Penny Stocks to Buy Using Technical Analysis for January 2022 Investopedia
Dec-11-21 11:59AM	Timothy P. Lynchs Stonepine Capital Portfolio: Top 10 Healthcare Stocks Insider Monkey
Nov-22-21 08:00AM	Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire
Nov-12-21 09:54AM	Catalyst Biosciences Down 40% After Announcing MarzAA Development Halt Investing.com -41.84%
09:24AM	What Is Happening With Catalyst Biosciences Shares Today? Benzinga
07:00AM	Catalyst Biosciences Announces Change in Corporate Strategy GlobeNewswire
Oct-29-21 08:00AM	Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences GlobeNewswire
Oct-28-21 03:05PM	Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +5.03%
Oct-13-21 04:05PM	Catalyst Biosciences Announces Chief Financial Officer Transition GlobeNewswire
Sep-28-21 04:01PM	FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency GlobeNewswire
Sep-24-21 08:00AM	Catalyst Biosciences to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-17-21 07:06AM	Here's Why We're A Bit Worried About Catalyst Biosciences' (NASDAQ:CBIO) Cash Burn Situation Simply Wall St.
Sep-15-21 08:00AM	Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital GlobeNewswire +5.64%
Sep-09-21 08:00AM	Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics GlobeNewswire
Sep-08-21 08:00AM	Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors GlobeNewswire
Aug-05-21 10:55AM	Catalyst Biosciences, Inc. (CBIO) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:00AM	Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Jul-29-21 03:05PM	Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-22-21 08:00AM	Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies GlobeNewswire
Jul-19-21 04:01PM	Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress GlobeNewswire
02:09AM	Reflecting on Catalyst Biosciences' (NASDAQ:CBIO) Share Price Returns Over The Last Five Years Simply Wall St.
Jul-14-21 08:00AM	Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company GlobeNewswire -6.74%
Jul-06-21 08:00AM	Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis GlobeNewswire
Jul-01-21 08:00AM	Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs GlobeNewswire
Jun-28-21 08:45AM	Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA Benzinga
08:00AM	Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency GlobeNewswire
Jun-21-21 06:00AM	KBR to Provide Engineering & Technical Services for NATO Allies Patriot System PR Newswire
Jun-10-21 08:00AM	Catalyst Biosciences to Participate in Two Upcoming Investor Conferences GlobeNewswire
May-20-21 02:57AM	What Type Of Shareholders Own The Most Number of Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares? Simply Wall St.
May-18-21 08:00AM	Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra GlobeNewswire
May-13-21 08:00AM	Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit GlobeNewswire
May-06-21 12:19PM	Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat? Zacks
09:23AM	Is a Surprise Coming for Catalyst Biosciences (CBIO) This Earnings Season? Zacks
09:15AM	Catalyst Biosciences, Inc. (CBIO) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:00AM	Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
May-05-21 12:29PM	What's in Store for Select Medical (SEM) Earnings in Q1? Zacks
08:00AM	Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors GlobeNewswire
Apr-28-21 08:00AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Catalyst Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors ACCESSWIRE
Apr-21-21 11:43AM	2 Strong Buy Penny Stocks That Could Deliver Massive Returns TipRanks +9.45%
Apr-19-21 08:00AM	Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the American Society of Hematology GlobeNewswire
Apr-12-21 08:00AM	Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders GlobeNewswire
Apr-07-21 04:05PM	Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-21-21 04:20AM	Will Catalyst Biosciences (NASDAQ:CBIO) Spend Its Cash Wisely? Simply Wall St.
Mar-04-21 08:00AM	Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update GlobeNewswire -5.91%
Feb-18-21 08:00AM	Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference GlobeNewswire -5.87%
Feb-11-21 04:01PM	Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock GlobeNewswire
Feb-10-21 10:05AM	Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021 Benzinga
Feb-03-21 08:00AM	Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress GlobeNewswire
Jan-29-21 04:01PM	Catalyst Biosciences Announces Closing of Public Offering of Common Stock GlobeNewswire
Jan-27-21 08:00AM	Catalyst Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire -9.16%
Jan-26-21 04:04PM	Catalyst Biosciences Announces Proposed Public Offering of Common Stock GlobeNewswire -7.32%
Jan-20-21 08:00AM	Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress GlobeNewswire
Jan-19-21 11:46PM	If You Had Bought Catalyst Biosciences' (NASDAQ:CBIO) Shares Five Years Ago You Would Be Down 81% Simply Wall St.
Jan-15-21 08:00AM	Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital GlobeNewswire
Dec-15-20 10:28PM	Is CBIO A Good Stock To Buy Now? Insider Monkey
Dec-07-20 08:00AM	Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference GlobeNewswire
Dec-03-20 04:02PM	Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs GlobeNewswire
08:50AM	Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study Zacks
Dec-02-20 08:00AM	Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors GlobeNewswire
Nov-30-20 10:44AM	Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod Zacks
10:42AM	Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies Zacks
Nov-25-20 10:15AM	5 Stocks to Keep an Eye on as Analysts Initiate Coverage Zacks
Nov-24-20 04:01PM	Catalyst Biosciences to Present at 32nd Annual Piper Sandler Virtual Healthcare Conference GlobeNewswire
Nov-12-20 08:50AM	Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences Zacks
Nov-11-20 07:57AM	5 Stocks Set to Pop on New Analyst Coverage Zacks
Nov-05-20 09:00AM	Catalyst Biosciences Announces Poster Presentation at the 62nd Annual American Society of Hematology Conference GlobeNewswire
08:00AM	Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Nov-03-20 08:00AM	Catalyst Biosciences to Present at Stifel 2020 Virtual Healthcare Conference GlobeNewswire

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience